Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients

Article English OPEN
Jana Held; Christian Supan; Carmen L. Ospina Salazar; Halidou Tinto; Léa Nadège Bonkian; Alain Nahum; Ali Sié; Salim Abdulla; Cathy Cantalloube; Elhadj Djeriou; Marielle Bouyou-Akotet; Bernhards Ogutu; Benjamin Mordmüller; Andrea Kreidenweiss; Mohamadou Siribie; Sodiomon B. Sirima; Peter G. Kremsner; (2017)
  • Publisher: BMC
  • Journal: Malaria Journal,volume 16 (issn: 1475-2875, eissn: 1475-2875)
  • Related identifiers: pmc: PMC5418711, doi: 10.1186/s12936-017-1832-x
  • Subject: Africa | RC955-962 | Choline analogue | Phase 2 | RC109-216 | P. falciparum | Infectious and parasitic diseases | SAR97276A | Malaria | Arctic medicine. Tropical medicine | Research
    mesheuropmc: parasitic diseases

Background Malaria remains one of the most important infectious diseases. Treatment options for severe malaria are limited and the choline analogue SAR97276A is a novel chemical entity that was developed primarily as treatment for severe malaria. Before starting clinica... View more
Share - Bookmark